Clinical Trial Update: Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating BCD-020 for indolent non-Hodgkin lymphomas has completed, assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Nodal Marginal Zone Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• BCD-020 (rituximab biosimilar)

Snippet

Sponsor: Biocad | Conditions: Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma | Phase 3 | Status: COMPLETED